Patent ID: 11912763
Assignee: L & L BIOPHARMA CO., LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 15:
16. An antibody targeting CLDN18.2, wherein the antibody targeting CLDN18.2 comprises alight chain variable region (VL) or a heavy chain variable region (VHI), wherein the VL comprises the following mutated complementary determining region (CDR) sequences: a VL CDR1 amino acid sequence as shown in SEQ ID NO: 11 or SEQ ID NO: 12; a VL CDR2 amino acid sequence as shown in SEQ ID NO: 13; and a VL CDR3 amino acid sequence as shown in SEQ TD NO: 14; and the mutated VHI comprises the following CDR sequences: a VH CDR1 amino acid sequence as shown in SEQ TD NO: 15, a VH CDR2 amino acid sequence as shown in SEQ TD NO: 16; and a VHI CDR3 amino acid sequence as shown in SEQ ID NO: 17, wherein mutation sequence of the CDR of the antibody targeting CLDN18.2 is a sequence with a deamination sensitive site mutation in a CDR region; the deamination sensitive site in the CDR region is position L30A or L30B of light chain CDR1; or, position H99 or H100 of heavy chain CDR3; amino acid residues at positions L30A and L30B of light chain CDR1 are mutated from NS to TS or NT, provided that position L30E is not Q and position L34 is not T; amino acid residues at positions H99 and H100 of heavy chain CDR3 are mutated from NS to TS or NT, provided that in light chain CDR1, position L30E is not Q and position L34 is not T.